SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BlossomHill Therapeutics, Inc. (Name of Issuer)

Common Stock, par value $0.0001 per share (Title of Class of Securities)

(CUSIP Number)

08/10/2026 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Vivo Innovation Fund II Holdings, L.P.
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 1,681,240.00 6 Shared Voting Power 0.00 7 Sole Dispositive Power 1,681,240.00 8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,681,240.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 5.5 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person:  The number represents shares of common stock, par value $0.0001 per share (the "Common Stock") of BlossomHill Therapeutics, Inc. (the "Issuer"), which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P. The percent is based on 30,643,660 shares of the Issuer's Common Stock outstanding (excluding the full exercise of the underwriters' over-allotment option) after the completion of the initial public offering, as reported in the Issuer's prospectus filed with the Securities and Exchange Commission (the "SEC") on August 7, 2026, pursuant to Rule 424(b)(4), which forms part of the Issuer's Registration Statement on Form S-1 (File No. 333-297512).

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Vivo Innovation II, LLC
2	Check the appropriate box if a member of a Group (see instructions)   (a)   (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 1,681,240.00 6 Shared Voting Power 0.00 7 Sole Dispositive Power 1,681,240.00 8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,681,240.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11	Percent of class represented by amount in row (9) 5.5 %
12	Type of Reporting Person (See Instructions) OO

Comment for Type of Reporting Person:  The number represents shares of Common Stock of the Issuer, which are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P. The percent is based on 30,643,660 shares of the Issuer's Common Stock outstanding (excluding the full exercise of the underwriters' over-allotment option) after the completion of the initial public offering, as reported in the Issuer's prospectus filed with the SEC on August 7, 2026, pursuant to Rule 424(b)(4), which forms part of the Issuer's Registration Statement on Form S-1 (File No. 333-297512).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BlossomHill Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 10255 Science Center Drive, Suite 200, San Diego, California 92121
Item 2.
(a)	Name of person filing: Vivo Innovation Fund II Holdings, L.P. and its General Partner Vivo Innovation II, LLC
(b)	Address or principal business office or, if none, residence: 192 Lytton Avenue, Palo Alto, CA 94301
(c)	Citizenship: Vivo Innovation Fund II Holdings, L.P. is a Delaware limited partnership. Vivo Innovation II, LLC is a Delaware limited liability company.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),        please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,681,240 shares of the Issuer's Common Stock are held of record by Vivo Innovation Fund II Holdings, L.P. Vivo Innovation II, LLC is the general partner of Vivo Innovation Fund II Holdings, L.P.
(b)	Percent of class: Vivo Innovation Fund II Holdings, L.P.: 5.5% Vivo Innovation II, LLC: 5.5%  %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Vivo Innovation Fund II Holdings, L.P.: 1,681,240 shares Vivo Innovation II, LLC: 1,681,240 shares
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: Vivo Innovation Fund II Holdings, L.P.: 1,681,240 shares Vivo Innovation II, LLC: 1,681,240 shares
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE
	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vivo Innovation Fund II Holdings, L.P.

Signature: /s/ Gaurav Aggarwal Name/Title: Gaurav Aggarwal/Managing Member of Vivo Innovation II, LLC, General Partner Date: 08/17/2026

Vivo Innovation II, LLC

Signature: /s/ Gaurav Aggarwal Name/Title: Gaurav Aggarwal/Managing Member Date: 08/17/2026

Exhibit Information

99.1 Joint Filing Statement

EXHIBIT 99.1

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Date: August 17, 2026

Vivo Innovation Fund II Holdings, L.P.

Vivo Innovation II, LLC